Objective: To assess the natural evolution of low-grade squamous intraepithelial lesions (LSIL) in a retrospective study conducted in a specialized primary care setting of patients detected from the cervical cancer prevention program. Materials and Methods: A review of all cytological examinations between January and December 2002, with 24 months follow-up was conducted in LSIL patients. Follow-up with cytological testing and colposcopy were performed every 6 months, and a biopsy was performed in cases that were indicated by protocol. Patients were not systemically or topically treated in any case. Results: During the study period, 4,152 women received cytology testing, and 122 had LSIL (prevalence, 2.9%). One hundred eleven patients (91%) completed the follow-up, and the remaining patients were lost for various reasons. The age distribution was as follows: 3.2% (G20 years), 34.4% (20Y29 years), 25.4% (30Y39 years), 27.2% (40Y49 years), 9% (50Y59 years), and 0.8% (960 years). Spontaneous regression was observed in 79 (71.3%) of women who completed follow-up. Regression was observed in 51.8% of patients within 12Y18 months and in 48.2% of patients within 18Y24 months of cytological testing. Regression according to age group was as follows: 100% (G20 years), 79.5% (20Y29 years), 60.6% (30Y39 years), 81.8% (40Y49 years), 90.9% (50Y59 years), and 100% (960 years). Conclusions: The general tendency of natural regression in LSIL patients without any specific risk factors identified is supported by our results.
2007, American Society for Colposcopy and Cervical Pathology
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.